Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting
| Autor: | Bermudez J, Garcia I, Urzaiz M, Marrero P, Cepero M, Llarena R, Martin J, Vivas-Perez J, Aliaga M, Soto A |
|---|---|
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | ACTAS UROLOGICAS ESPANOLAS r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) r-FISABIO. Repositorio Institucional de Producción Científica instname |
| ISSN: | 0210-4806 |
| Popis: | Introduction and objectives: Nivolumab is an immunotherapy agent that has been an approved treatment for previously treated patients with advanced renal cell carcinoma (RCC). Experience in real-life settings, especially regarding immune-related adverse events, is scarce. We present our experience with reference to the safety of nivolumab in patients with metastatic RCC (mRCC) treated in 9 hospitals in Spain. Material and methods: Retrospective, multicentre study of patients with mRCC treated with nivolumab between 2016 and 2018. Data on baseline socio-demographic and clinical characteristics and drug-related adverse events were collected. Results: The mean age of the 26 patients included was 63.7 11.5 years; 96% were ECOG 0-1 and 78% had favourable or intermediate MSKCC risk scores; 73% had the clear cell histological subtype and 30% metastatic disease. Median follow-up was 9 months (range 1-14). All patients experienced an adverse event at different grades, with fatigue, fever and anaemia being the most common (27%). Grade 3 adverse events occurred in 23% of patients. Adverse reactions led to treatment suspension in 3 patients (11%). Conclusion: In the real-life clinical setting, nivolumab shows favourable outcomes, similar to those reported by other studies. (C) 2019 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|